TScan Therapeutics (NASDAQ:TCRX) Given New $9.00 Price Target at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX) had its price objective reduced by Needham & Company LLC from $11.00 to $9.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also commented on TCRX. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Wedbush restated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Monday, December 23rd.

TScan Therapeutics Stock Down 5.0 %

TCRX opened at $1.92 on Wednesday. The company has a fifty day moving average price of $2.45 and a 200-day moving average price of $4.06. The firm has a market capitalization of $102.47 million, a P/E ratio of -1.81 and a beta of 0.87. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a one year low of $1.82 and a one year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Equities research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TCRX. Checkpoint Capital L.P. purchased a new position in TScan Therapeutics in the third quarter worth $4,110,000. abrdn plc grew its position in TScan Therapeutics by 137.8% in the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after acquiring an additional 512,049 shares in the last quarter. State Street Corp grew its position in TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after acquiring an additional 148,414 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock worth $851,000 after purchasing an additional 145,731 shares during the last quarter. Finally, Lynx1 Capital Management LP lifted its stake in TScan Therapeutics by 2.5% in the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock worth $16,286,000 after purchasing an additional 132,747 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.